

Supplementary data

Supplementary Appendix 1. Search strategy for systematic review.

PubMed

((Coronary[Title/Abstract]) AND (In-Stent[Title/Abstract])) AND (Restenosis[Title/Abstract])

Scopus

TITLE-ABS-KEY (coronary) AND TITLE-ABS-KEY (in-stent) AND TITLE-ABS-KEY (restenosis) AND (LIMIT-TO (DOCTYPE , "ar") OR LIMIT-TO (DOCTYPE , "le")) AND (LIMIT-TO (SUBJAREA , "MEDI")) AND (LIMIT-TO (SRCTYPE , "j") OR LIMIT-TO (SRCTYPE , "p"))

Web of Science

((TS=(Coronary)) OR TI=(Coronary)) OR AB=(Coronary)

((TS=(In-Stent)) OR TI=(In-Stent)) OR AB=(In-Stent)

((TS=(Restenosis)) OR TI=(Restenosis)) OR AB=(Restenosis)

#1 AND #2 AND #3

Document Type: Articles or Proceedings Paper or Meeting Abstracts

Ovid

(Coronary and In-Stent and Restenosis).ti,ab,kw.

1 and "Clinical Trial" [Publication Type]

1 and "Randomised Controlled Trial" [Publication Type]

1 and "Comparative Study" [Publication Type]

1 and "Clinical Study" [Publication Type]

1 and "Controlled Clinical Trial" [Publication Type]

2 or 3 or 4 or 5

Supplementary Table 1. Randomised Controlled Trials on the treatment of in-stent restenosis: Trial Characteristics

Trial Characteristics					Baseline Characteristics				
First Author/Trial (Ref. #)	Year	Stent	Therapy	n	Age (years)	DM (%)	Length (mm)	RVD (mm)	MLD (mm)
Teirstein et al. (95)	1997	BMS	IVBT	26	70	27.0	12.9	2.88	1.10
			BA/BMS	29	69	41.0	11.9	2.78	1.03
WRIST (150)	2000	BMS	IVBT	65	63	39.0	28.8	2.71	0.94
			PCI	65	62	45.0	26.7	2.72	0.81
GAMMA-ONE (94)	2001	BMS	IVBT	131	58	31.0	19.0	2.69	0.98
			PCI	121	61	31.0	20.3	2.73	0.96
ARTIST (103)	2002	BMS	BA	146	61	25.0	13.6	2.65	0.53
			RA	152	62	26.0	13.6	2.63	0.54
RESCUT (88)	2003	BMS	CB	214	62	24.0		2.58	0.83
			BA	214	61	27.0		2.53	0.84
RIBS I (115)	2003	BMS	BMS	224	61	27.0	12.7	2.87	0.68
			BA	226	61	26.0	13.0	2.83	0.67
Long WRIST (93)	2003	BMS	PCI	60	61	37.0	29.1	2.55	0.70
			IVBT	60	63	42.0	29.2	2.57	0.80
OSIRIS (125)	2004	BMS	BA	102	65	27.5		2.61	
			SIR	99	65	27.3		2.60	
			SIRhd	99	65	32.2		2.57	
Ragosta et al. (151)	2004	BMS	BA	29	63	21.0	5.1	3.02	0.79
			BMS	29	64	10.0	7.3	3.12	0.85
			RA	30	59	47.0	20.6	2.81	0.69

			BMS	25	59	32.0	18.2	2.99	0.79
Montorsi et al. (152)	2004	BMS	BA	25	61			3.19	1.07
			CB	25	66			3.28	0.93
ROSTER (104)	2004	BMS	RA	100	63	31.0	18.6	2.85	0.82
			BA/BMS	100	65	30.0	16.7	2.82	0.92
Alfonso et al. (86)	2005	BMS	BMS	20	66	40.0	12.8	2.55	0.91
			BA	20	66	30.0	12.0	2.55	1.00
ISAR-DESIRE (42)	2005	BMS	DES-S	100	63	31.0	12.4	2.60	0.91
			DES-P	100	65	27.0	11.5	2.60	0.97
			BA	100	64	25.0	12.3	2.57	0.95
PACCOCATH-ISR (153)	2006	BMS	DCB	26	64	15.0	17.9	2.94	0.75
			BA	26	64	15.0	18.1	2.95	0.67
RIBS II (57)	2006	BMS	DES	76	64	38.0	16.9	2.66	0.74
			BA	74	64	31.0	15.7	2.68	0.70
SISR (59)	2006	DES-BMS	DES	259	63	33.3	17.2	2.62	0.78
			IVBT	125	64	29.6	16.8	2.64	0.86
TAXUS V ISR (60)	2006	BMS	IVBT	201	63	30.3	15.0	2.61	0.83
			DES-P	195	63	40.0	15.9	2.68	0.80
INDEED (61)	2007	BMS	DES	65	61	30.8	27.5	2.77	0.78
			IVBT	64	60	31.3	27.8	2.67	0.81
PEPCAD II (154)	2009	DES-BMS	DCB	66	65	33.3	15.7	2.85	0.74
			DES	65	65	26.2	15.4	2.83	0.77
ISAR-DESIRE 2 (43)	2010	DES	DES-P	225	67	38.8	12.5	2.75	0.95
			DES-S	225	66	38.2	12.7	2.78	1.02
Habara et al. (66)	2011	DES	DCB	25	70	56.0	12.7	2.69	0.99
			BA	25	69	68.0	13.2	2.90	0.92

Wiemer et al. (155)	2011		DES	44	65	49.0	25.2	2.89	0.70
			IVBT	47	64	49.0	17.2	2.77	0.85
PEPCAD- DES (69)	2012	DES	DCB	72	70	36.1	11.2	2.29	0.66
			BA	38	64	34.2	12.2	2.30	0.62
Song et al. (156)	2012	DES	CB	48	62	31.2	7.5	2.93	0.80
			DES-S	48	65	37.5	8.6	3.18	0.68
			S-DES-d	32	61	25.0	22.2	3.19	0.94
			E-DES-d	34	65	35.3	22.5	3.43	0.75
CRISTAL (58)	2012	DES	DES-S	136	68	39.0	14.6	2.60	1.09
			BA	61	67	38.0	13.4	2.50	1.58
ISAR-DESIRE 3 (44)	2013	DES	DCB	137	68	41.0		2.75	0.97
			DES-P	131	69	47.0		2.80	0.93
			BA	134	67	37.0		2.72	0.88
Habara et al. (70)	2013	DES/BMS	DCB	137	68	46.0	12.8	2.52	0.86
			BA	71	70	42.0	13.7	2.49	0.84
RIBS V (157)	2014	BMS	DCB	95	67	32.0	13.7	2.64	1.02
			DES-E	94	64	20.0	13.8	2.64	0.93
PEPCAD-CHINA ISR (158)	2014	DES	DCB	109	62	40.0	12.5	2.66	0.85
			DES-P	106	62	33.0	13.8	2.72	0.86
SEDUCE (159)	2014	BMS	DCB	25	68	24.0		3.00	0.98
			DES-E	25	64	4.0		2.85	0.57
RIBS IV (160)	2015	DES	DCB	154	66	49	10.4	2.59	0.79
			DES-E	155	66	43	10.7	2.67	0.75
PATENT-C (81)	2015	BMS	Standard Scoring Balloon	28	64	35.7	13.8	2.54	0.73
			Paclitaxel Coated Scoring Balloon	33	65	42.4	16.5	2.72	0.90

TIS (161)	2016	BMS	DCB	68	65.6	25.0	22.5	2.64	0.92
			DES-E	68	65.5	26.5	28.5	2.66	0.79
RESTENT- ISR (162)	2016	DES	DES-E	158	64.1	36.7	22.5	3.07	0.78
			DES-Z	146	62.2	36.3	24.7	3.15	0.89
ISAR-DESIRE 4 (80)	2017	DES	Scoring Balloon pre DCB	125	69.4	40.8		2.96	1.01
			Standard Treatment pre DCB	127	69.4	43.3		2.89	0.94
DARE (163)	2017	DES-BMS	DCB	137	66	42		2.56	0.77
			DES-E	141	65	46		2.59	0.79
RESTORE (164)	2017	DES	DCB	86	67	50.0	18.1	2.85	0.63
			DES-E	86	66	44.2	17.4	3.06	0.63
BIOLUX-RCT (165)	2018	DES-BMS	DCB	157	67.2	30.6	5.8	3.0	1.0
			DES	72	69.4	33.3	7.2	2.9	0.9
RESTORE ISR CHINA (67)	2018	DES	RESTORE DCB	120	63.6	38.3	16.5	2.79	0.91
			SEQUENT PLEASE DCB	120	63.9	38.3	16.2	2.71	0.90
Ali et al. (79)	2019	DES	PACLITAXEL DCB	25	58.6	76	13.3	2.42	0.80
			SIROLIMUS DCB	25	61.6	72	14.2	2.53	0.81
ELEGANT (91)	2019	DES-BMS	NON-SLIP BALLOON PRE DCB	105	70.0	51.4	13.8	2.56	0.93
			HPNCB PRE DCB	105	68.9	47.6	13.3	2.54	0.91
Sato et al. (102)	2019	DES-BMS	ELCA + DCB	20	69.0	50.0	13.9	2.75	0.67
			DCB	20	69.1	75.0	15.5	2.83	1.00

AGENT ISR (68)	2019	DES-BMS	Agent DCB	65	68	36.9	11.7	2.60	0.75
			SeQuent DCB	60	69	36.7	13.3	2.48	0.65

Supplementary Table 2. Randomised Controlled Trials on the treatment of in-stent restenosis: Angiographic and Clinical Endpoints

Trial Characteristics				Angiographic Endpoints						Clinical Endpoints				
First Author/Trial (Ref. #)	Year	Therapy	Time (months)	RE (%)	ISTLL (mm)	ISGLL (mm)	MLD (mm)	DS (%)	Time (months)	MACE (%)	Death (%)	MI (%)	TLR (%)	TVR (%)
Teirstein et al. (95)	1997	IVBT	6	17*	0.38*		2.43*	17.0*	12	15.0*	0.0	4.0	12.0*	
		BA/BMS		54	1.03		1.85	37.0		48.0	3.0	0.0	45.0	
WRIST (150)	2000	IVBT	6	22*	0.22*		2.03*	30.0*	12	35.3*	6.2	9.2	23.0*	33.8*
		PCI		60	1.00		1.24	57.0		67.3	6.2	9.2	63.1	67.6
GAMMA-ONE (94)	2001	IVBT	6	32*	0.73*		1.78*	46.0*	9	28.2*	3.1	9.9	24.4*	31.3*
		PCI		55	1.14		1.37	53.0		43.8	0.8	4.1	42.1	46.3
ARTIST (103)	2002	BA	6	51*	0.67*		1.20*	56.0*	6	20.4			31.0	
		RA		64	0.91		0.99	63.0		9.9*			39.0	
RESCUT (88)	2003	CB	7	30	0.56		1.61	39.0	7	16.4	1.4	1.4	13.5	
		BA		31	0.62		1.55	40.0		15.4	0.9	1.4	13.1	
RIBS I (115)	2003	BMS	6	38	1.12	1.06	1.63	45.0	12	23.0	4.0	2.2		19.6
		BA		39	0.73*	0.72	1.52	46.0		29.0	3.0	5.3		24.3
Long WRIST (93)	2003	PCI	4-8	73	0.99	0.85	0.93	65.0	12	63.3	1.7	18.3	61.7	
		IVBT		45*	0.67*	0.65*	1.23	54.0*		42.2*	6.8	23.7	39.0*	
OSIRIS (125)	2004	BA	6	42	0.60		1.53	43.7	12	27.5	0.0	1.0		25.5
		SIR		39	0.72		1.37	45.8		29.3	3.0	0.0		24.2
		SIRhd		22*	0.49*		1.66*	38.1		18.2	2.0	0.0		15.2
Ragosta et al. (151)	2004	BA							9	21.0	0.0	7.2		17.0
		BMS						7.0		3.6	3.6		3.6	
		RA						43.0		6.6	3.3		40.0	
		BMS						32.0		0.0	4.0		32.0	
Montorsi et al. (152)	2004	BA							6	28.0	0.0		40.0	
		CB						17.0		0.0		12.5*		
ROSTER (104)	2004	RA	9	42					12	38.0*	2.0	3.0	32.0	
		BA/BMS		56						52.0	2.0	3.0	45.0	
	2005	BMS							23	25.0	5.0	0.0		20.0

Alfonso et al. (86)		BA								50.0	15.0	10.0		35.0
ISAR-DESIRE (42)	2005	DES-S	6-8	14*	0.10	0.30	2.12	23.1	12	11.0	2.0	1.0		8.0
		DES-P		22*	0.26	0.55	2.02	26.6		22.0	1.0	2.0		19.0
		BA		45			1.40	45.8		36.0	3.0	0.0		33.0
PACCOCATH-ISR (153)	2006	DCB	6	5*	0.09*	0.03*	2.31		12	4.0*	4.0	4.0	0.0*	
		BA		43	0.76	0.74	1.60			31.0	0.0	8.0	23.0	
RIBS II (57)	2006	DES	9	11*		0.13	2.52	8.0	12	11.8*	3.9	2.6		10.5*
		BA		39		0.69	1.54	40.0		31.1	4.1	2.7		29.7
SISR (59)	2006	DES	6	20	0.33	0.23	1.80	32.35	9	10.0*	0.0	0.4	8.5*	10.8*
		IVBT		30	0.27	0.33	1.52	40.97		19.2	0.0	0.0	19.2	21.6
TAXUS V ISR (60)	2006	IVBT	9	31		0.27	1.55	31.2	9	20.1	0.5	4.6	20.1	23.7
		DES-P		15*	0.25	0.11*	1.99	14.5		11.5*	0.0	3.7	7.9 *	12.0 *
INDEED (61)	2007	DES	6	6*	0.15*	0.23	2.29	20.42	12	7.7	3.1	1.5	4.6*	
		IVBT		21	0.55	0.40	1.76	32.61		18.8	0.0	0.0	18.8	
PEPCAD II (154)	2009	DCB	6	4.0	0.19*	0.17*	2.08	29.4	12	7.6	1.5	0.0	6.3	
		DES		12.0	0.45	0.38	2.11	34.2		16.9	0.0	1.5	15.4	
ISAR-DESIRE 2 (43)	2010	DES-P	6-8	21.0	0.38	0.25	2.16	25.4	12	19.6	4.5	1.8	13.8	
		DES-S		19.0	0.40	0.26	2.14	26.6		20.4	3.4	2.7	14.3	
Habara et al. (66)	2011	DCB	6	9.0*	0.18*	0.17*	1.82	34.2	6	4.3*	0.0	0.0	4.3*	
		BA		63.0	0.72	0.72	1.28	58.0		41.7	0.0	0.0	41.7	
Wiemer et al. (155)	2011	DES	6	4.0*	0.09*		2.66	7.78	12	4.0	2.0	0.0	2.0	2.0
		IVBT		23.0	0.39		1.75	36.9		27.0	2.0	6.0	16.0	19.0
PEPCAD- DES (69)	2012	DCB	6	17.0	0.43	0.32	1.75	29.6	6	16.7*	1.4	0.0	15.3*	
		BA		58.0	1.03	0.99	1.10	51.1		50.0	10.5	2.6	36.8	
Song et al. (156)	2012	CB	9	21.0	0.30	0.25	2.08	16.5	12	6.3	0.0	0.0	6.3	6.3
		DES-S		3.0	0.02	0.06*	2.57	12.5		6.3	0.0	6.3	0.0	0.0
		S-DES-d		5.0	0.13	0.13	2.58	25		9.6	3.1	3.1	3.1	3.1
		E-DES-d		14.0	0.07*	0.07	2.71	18		8.8	2.9	2.9	5.8	5.8
CRISTAL (58)	2012	DES-S	12	11.0	0.37		2.14*	21.0*	12		2.2	2.9	5.9	2.2
		BA		14.0	0.41		1.71	29.8			1.6	1.6	13.1	0.0
	2013	DCB	6-8	27.0*	0.37		1.79	38		23.5	2.2	2.1	22.1	24.2

ISAR-DESIRE 3 (44)		DES-P		24.0*	0.34		1.82	37.4		19.3	4.6	2.4	13.5	16.6
		BA		57.0	0.70		1.26	54.1		46.2	5.3	1.5	43.5	45.1
Habara et al. (70)	2013	DCB	6	4.3*	0.11*	0.18*	1.87*	28.1*	6	6.6*	0.0	0.0	2.9*	6.6*
		BA		31.9	0.49	0.72	1.42	44.1		31.0	0.0	0.0	31.0	31.0
RIBS V (157)	2014	DCB	6	9.5		0.14	2.03	24	12	8.0	4.0	3.0	6.0	6.0
		DES-E		4.7		0.04	2.44*	13*		6.0	0.0	4.0	1.0	2.0
PEPCAD-CHINA ISR (158)	2014	DCB	9	18.6	0.54	0.46	1.80	29	12	16.5	0.0	3.7	14.7	16.5
		DES-P		23.8	0.62	0.55	1.76	31		16.0	2.0	6.6	10.4	16.0
SEDUCE (159)	2014	DCB	9	9.1	0.28	0.16	2.13	26.4	12		4.2	0	4.2	8.3
		DES-E		0.0	0.07	0.08	2.54*	11.4*			4	4	8	16.0
RIBS IV (160)	2015	DCB	9	19		0.30	1.80	30	12	18	1.9	3.0	13.0	16.2
		DES-E		11		0.18	2.03*	23*		10*	2.6	1.3	4.5*	8.4*
PATENT-C (81)	2015	Standard Scoring Balloon	6	40.7		0.48	1.39	46.8	6	32.1	Cardiac Death	TVMI	32.1	-
		Paclitaxel Coated Scoring Balloon		7.4*		0.17*	1.80*	33.7*		6.1*	Cardiac Death	TVMI	3.0*	-
TIS (161)	2016	DCB	12	8.7		0.09*	2.09	26.2	12	10.3	Cardiac Death	1.5	-	7.4
		DES-E		19.1*		0.44	2.07	30.9		19.1	Cardiac Death	1.5	-	16.2
RESTENT- ISR (162)	2016	DES-E	9		0.40		2.54	16.7	36	10.1	0.6	1.9	14.5	
		DES-Z			0.45		2.53	17.4		9.6	2.1	2.7	21.2	
ISAR-DESIRE 4 (80)	2017	Scoring Balloon pre DCB	6-8	18.5*		0.31	1.95	35*	12	18.4	1.6	3.2	16.2	-
		Standard Treatment pre DCB		32.0		0.41	1.77*	40.4		23.3	1.7	1.6	21.8	-
DARE (163)	2017	DCB	6	18.1		0.17*	1.71	36.1	12	10.9	0.7	2.2	-	8.8
		DES-E		20.9		0.45	1.74	33.8		9.2	1.4	2.8	-	7.1
	2017	DCB	9	19.5	0.20	0.15	1.8*	34	12	7.0	0.0	1.2	5.8	5.8

RESTORE (164)		DES-E		5.6	0.27	0.19	2.09	26		4.7	0.0	3.5	1.2	1.2
BIOLUX-RCT (165)	2018	DCB	6		0.03	-0.02	2.2.	28.5	18	17.9	Cardiac Death	TVMI	-	13.5
		DES			0.20	0.13	2.2	23.7*		18.6	Cardiac Death	TVMI	-	11.6
RESTORE ISR CHINA (67)	2018	RESTORE DCB	9	24.6	0.48	0.39	1.64	38.9	12	13.3	0.0	2.5	13.3	23.3
		SEQUENT PLEASE DCB		18.8	0.42	0.35	1.71	34.5		12.6	0.0	3.4	11.8	12.6*
Ali et al. (79)	2019	PACLITAXEL DCB	6	-	0.37	0.31	1.99	19.9	12	16	0.0	-	16	-
		SIROLIMUS DCB		-	0.26	0.18	1.99	17.8		12	0.0	-	12	-
ELEGANT (91)	2019	NON-SLIP BALLOON PRE DCB	8	12.9	-	0.28	1.82	30.4	8	7.0	1.0	0.0	6.0	7.0
		HPNCB PRE DCB		15.2	-	0.27	1.71	33.1		9.7	3.9	1.9	7.8	9.7
Sato et al. (102)	2019	ELCA + DCB	12	20	-	-0.25	-	-	12	-	-	-	10.0	-
		DCB		20	-	-0.33	-	-		-	-	-	20.0	-
AGENT ISR (68)	2019	Agent DCB	6	13.7	0.397		1.62	20.7	12		3.1	4.6	7.7	9.2
		SeQuent DCB		22.4	0.393		1.51	20.2			1.7	3.3	10.0	11.7

Supplementary Table 1 and Supplementary Table 2 Legend

Details of the literature search are given in the Methods. The primary endpoint of each trial is highlighted in bold. * =p value <0.05.

ARTIST: Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial; AGENT ISR: Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis; BA: balloon angioplasty; IVBT: intravascular brachytherapy; BIOLUX: Clinical Performance of the Pantera LUX Paclitaxel Releasing Balloon Versus the Drug Eluting Orsiro Hybrid Stent System in Patients With In-stent Restenosis; CB: cutting balloon; CRISTAL: A Prospective, Randomised, Multi-Center Comparison of the CYPHER Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients With Intra-Des Restenosis; DARE: Drug Eluting bAlloon for In-stent REstenosis. Multi-center, Randomised Trial to Study the Effect of the SeQuent Please Drug-eluting Balloon Versus the XIENCE Prime Drug-eluting Stent for the Treatment of In-stent Restenosis; DCB: drug-coated balloon; DES: drug-eluting stent(s); DES-E: everolimus drug eluting stent(s); DES-P: paclitaxel drug-eluting stent(s); DES-S: sirolimus drug-eluting stent(s); DM: diabetes mellitus; E-DES-d: everolimus-eluting stent for diffuse restenosis; ELEGANT: Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions; INDEED: Treatment of diffuse IN-stent restenosis with Drug-Eluting stents vs. intracoronary bEta-raDiation therapy; ISAR-DESIRE: Intracoronary Stenting or Angioplasty for Restenosis Reduction: Drug-Eluting Stents for In-Stent Restenosis; ISAR-DESIRE 2: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2); ISAR-DESIRE 3: Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 3; ISTLL: in-stent late loss; ISGLL: in-segment late loss; LL: lesion length; Long WRIST: Washington Radiation for In-Stent Restenosis Trial for Long Lesions; MACE: major adverse cardiac events (including death or cardiac death, myocardial infarction [MI], and target lesion revascularisation [TLR] or target vessel revascularisation [TVR] as considered in each trial for the combined outcome measure); MLD: minimal lumen diameter; OSIRIS: Oral Sirolimus to Inhibit Recurrent In-stent Stenosis; PACCOCATH-ISR: Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons; PATENT-C: Treatment of Coronary In-stent Restenosis by a Paclitaxel Coated

AngioSculpt Scoring Balloon; PCI: percutaneous coronary intervention (BA, rotational atherectomy [RA], excimer coronary laser atherectomy [ECLA] , BMS); PEPCAD: The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel Coronary Artery Disease. A Pilot Study; PEPCAD II: The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses: A Comparison to the Paclitaxel-Eluting Taxus™ Stent. A Pilot Study; PEPCAD-CHINA: A Multicenter, Randomized, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of the Treatment of In-stent Restenosis Lesion by Paclitaxel-eluting PTCA- Balloon Catheter Versus Paclitaxel-eluting Stent; PEPCAD DES: Treatment of DES-In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting PTCA Catheter; RA: rotational atherectomy; RE: binary restenosis; RESCUT: Restenosis Cutting Balloon Evaluation Trial; RESTENT ISR: Prospective, Single-blinded, Randomized Comparison of the Clinical and Angiographic Results With Intravascular Analysis of Everolimus-Eluting Versus Zotarolimus-Eluting stents for In-Stent Restenosis(ISR) Lesions: Volumetric Analysis With Intravascular Ultrasound (IVUS): Phase IV Multicenter Trial; RESTORE: Treatment of Drug-Eluting Stent REstenosis Using Drug-Eluting STents vs. Drug-COated Balloon for Preventing REcurrent In-Stent Restenosis; RESTORE CHINA: Compare the Efficacy and Safety of RESTORE DEB and SeQuent Please in Chinese Patient With Coronary In-stent Restenosis; RIBS I: Restenosis Intra-stent Balloon Angioplasty Versus Elective Stenting; RIBS II: Restenosis Intra-stent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting; RIBS V: Restenosis Intra-stent: Drug-eluting Balloon vs. Everolimus-eluting Stent; ROSTER: Randomized Trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-Stent Restenosis; RVD: reference vessel diameter; S-DES-d: sirolimus-eluting stent for diffuse restenosis; SEDUCE: Safety and Efficacy of a Drug eluting balloon in Coronary artery rEstenosis; SIR: usual dose oral sirolimus; SIRhd: high-dose oral sirolimus; SISR: Sirolimus-Eluting Stent vs. Brachytherapy in Patients With Bare Metal In-Stent Restenosis; TAXUS V ISR: A Prospective, Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis; TIS: Treatment of Coronary In-Stent Restenosis; WRIST: Washington Radiation for In-Stent restenosis Trial